Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
achondroplasia
MeSH D000130 - achondroplasia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D004392:
Dwarfism
11 Companies
2 Drugs
$
Success rate
D010009:
Osteochondrodysplasias
0 Companies
0 Drugs
Success rate
D000130:
Achondroplasia
1 Company
1 Drug
$
Success rate
D013796:
Thanatophoric dysplasia
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
BioMarin Pharmaceutical
Vosoritide
Voxzogo
2030-05-20
2021-11-19
$672.332 M
Q4/23-Q3/24
Clinical Trials
Historical Success Rate
Phase 1
100
%
1/1
Phase 2
33
%
1/3
Phase 3
100
%
3/3
Approved:
2
Overall Success rate:
33%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
BioMarin Pharmaceutical
Vosoritide
,
Ademetionine
,
Sodium chloride
,
Aspartame
,
Diluent
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use